康哲药业携手新交所 共话新兴市场产业国际化与医药出海新范式探索
Jul 18, 2025 13:00 HKT |  |
|
耀啟新程！康哲藥業今日於新加坡交易所主板實現二次上市
Jul 15, 2025 17:05 HKT | |
|
耀启新程！康哲药业今日于新加坡交易所主板实现二次上市
Jul 15, 2025 16:53 HKT | |
|
Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 21:27 HKT |  |
|
康哲藥業建議於新加坡交易所第二上市
Jun 25, 2025 18:13 HKT | |
|
康哲药业建议于新加坡交易所第二上市
Jun 25, 2025 17:24 HKT | |
|
康希諾重磅推出優佩欣疫苗 為兒童健康保駕護航的創新之選
Jun 21, 2025 12:09 HKT | |
|
康希诺重磅推出优佩欣疫苗 为儿童健康保驾护航的创新之选
Jun 20, 2025 17:58 HKT | |
|
Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited
May 14, 2025 15:00 HKT |  |
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
Apr 24, 2025 18:43 HKT |  |
|
君圣泰医药三项创新研究成果即将亮相2025欧肝会(EASL)
Apr 24, 2025 18:35 HKT | |
|
熊去氧胆小檗碱（HTD1801）一药多效 即将进入商业化新纪元
Apr 15, 2025 08:10 HKT | |
|
熊去氧膽小檗堿（HTD1801）一藥多效 即將進入商業化新紀元
Apr 15, 2025 08:10 HKT | |
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
Apr 15, 2025 08:00 HKT | |
|
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong
Mar 25, 2025 23:34 HKT | |
|
收入狂飙同比增长137% 多款产品蓄势以待 康希诺增长动能充沛
Mar 25, 2025 23:22 HKT | |
|
MASH疾病領域的大市場、大需求
Mar 20, 2025 11:53 HKT | |
|
MASH疾病领域的大市场、大需求
Mar 19, 2025 18:34 HKT | |
|
康哲藥業（00867）發佈2024年度業績：聚焦創新與專科突破 重塑增長動能
Mar 19, 2025 18:19 HKT | |
|
康哲药业（00867）发布2024年度业绩：聚焦创新与专科突破 重塑增长动能
Mar 19, 2025 18:06 HKT | |
|
|
Next >>
|